ClinicalTrials.gg
RecruitingNCT07932860PENG blockUpdated Nov 12, 2026

Comparison Between Ultrasound Guided Pericapsular Nerve Block And Suprainguinal Fascia Iliaca Nerve Block in Hip Surgery

An interventional study of PENG and Fascia iliaca in Anesthesia, Local, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Jan 2022, registered Nov 2026).
  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Nov 12, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hip fracture is a common orthopedic emergency in the elderly, and it is associated with significant morbidity and mortality. Surgical reduction and fixation are the definitive treatment in most patients, effective perioperative analgesia that minimizes the need for opioids and related adverse effects (such as delirium) is essential in this patient population.

In this study we are going to compare the effects of ultrasound guided pericapsular nerve group (PENG) block and suprainguinal fascia iliaca compartment block (FICB) on postoperative analgesia and quadriceps strength following total hip arthroplasty.

Read the detailed description

Total hip replacements (THRs) are quite successful surgery for many end-stage hip diseases in terms of pain relief and functional recovery (Lindberg-larsen M et al,2020). However, THR are associated with severe perioperative pain which prolongs length of hospitalization and increases the morbidity and medical cost (Guarino AJ et al,2019). Adequate pain management is crucial for improving the satisfaction of patients and clinical outcomes. Numerous strategies have been implemented to reduce postoperative pain following THR including local infiltration analgesia, epidural analgesia, intravenous non-steroidal anti-inflammatory agents and peripheral nerve block. (Kuchalik J et al,2017).

So, multimodal analgesia has been extensively used in perioperative period of THR (Berninger MT etal, 2019).

One of the regional anesthesia options for hip surgery is the fascia iliaca compartment block (FICB) that affects nerves important for hip innervation and sensory innervation of the thigh - femoral, obturator and lateral femoral cutaneous nerve.(Standring S,2015). FICB can be easily performed and is often a good solution for management of hip fractures in emergency departments. Its use reduces morphine pre-operative requirement for patients with femoral neck fractures and can also be indicated for hip arthroplasty, hip arthroscopy and burn management of the region (Madabushi R, 2016). A suprainguinal FICB produces a more complete sensory block of the medial, anterior and lateral region of the thigh when compared to infra-inguinal FICB. Additionally,supra-inguinal FICB leads to a more consistent spread in the cranial direction, thus spreading the anesthetic more consistently towards the lumbar plexus and three targeted nerves. So,the supra-inguinal approach has a superior postoperative analgesic efficacy compared to infra-inguinal approach along with significantly less morphine consumption in the first 24(Garner M,2017).

The pericapsular nerve group (PENG) block, which targets sensory branches of the obturator, accessory obturator, and femoral nerves in the anterior capsule of the hip, has been proposed as an effective method to treat pain associated with hip fractures and total hip arthroplasty(THA)(Giron-Arango L,2018). The PENG block provides coverage of the sensory nerves supplying the anterior hip while sparing motor blockade of the quadriceps; a known complication of fascia iliaca and femoral blocks (Tran J,2019).

PENG block has potential advantages over traditional forms of regional analgesia for pain originating from the hip, such as femoral nerve or fascia iliaca blocks. One of these potential advantages include a wider and more complete coverage of sensory nerves innervating the hip, leading to more effective regional analgesia with the potential to reduce postoperative pain,increase patient satisfaction and allow early mobilization(Bartels K,2016).

02

Conditions studied

  • Anesthesia, Local
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,953 studies on the registry; 430 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for hip surgeries.
  • Age: patients aged ≥ 18 years old from both sexes.
  • Patients physical status (ASA) class I-III.

Exclusion criteria

Exclusion Criteria:

  • - Refusal of procedure or participation in the study.
  • Patients suffering from allergy to local anestheics.
  • Patients with coagulation disorders or those on anticoagulant medication.
  • Infection in punctured site.
  • Classified as either (ASA) class IV-V
  • Patients suffering from cardiac condition,dementia or cognitive impairment, liver failure, renal insufficiency and pre-existing neurologic deficits.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    group P

    patients receiving Peng block.

    Procedure: PENG

  • Experimental
    Group F

    patients receiving suprainguinal Fascia iliaca block.

    Procedure: Fascia iliaca

Interventions

  • ProcedurePENG

    patients receiving Peng block.

  • ProcedureFascia iliaca

    patients receiving suprainguinal Fascia iliaca block

06

What researchers measure

Primary outcomes

  1. pain score(VAS score)

    The primary outcome measure was pain scores(VAS score) from 0(no pain) till 10 severe pain

    Time frame: 24 hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid Use and Storage Patterns by Patients after Hospital Discharge following Surgery. PLoS One. 2016 Jan 29;11(1):e0147972. doi: 10.1371/journal.pone.0147972. eCollection 2016. PubMed 26824844 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Dec 2027, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 12, 2026
StartActual
Jan 1, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07932860
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Jan 1, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

dalia tarek elshahawy, MSC
Contact
dr.daliaelshahawy@gmail.com
+201062128018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion